文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

高危前列腺癌盆腔放疗联合中度大分割前列腺推量(MOB-RT)的2期研究:急性安全性与生活质量

Moderate hypofractionated boost to the prostate with pelvic radiotherapy in high-risk prostate cancer (MOB-RT) - a phase 2 study: acute safety and quality of life outcomes.
PubMed 文献 · Radiother Oncol · 2026-05-23

这项前瞻性单臂2期研究纳入100例高危或淋巴结阳性前列腺癌患者,接受前列腺及盆腔 elective 淋巴结照射的中度大分割放疗(前列腺60 Gy/20次,ENI 48 Gy)联合ADT,允许对前列腺内大体病灶推量至68 Gy、对影像学受累淋巴结推量至55 Gy。主要终点为放疗后3个月急性胃肠道(GI)副作用(CTCAE v5.0),预设急性≥2级GI副作用不超过35%。结果显示急性≥2级GI副作用发生率为15.5%(单侧95%置信上限22.8%),≥2级急性泌尿生殖(GU)副作用为26.8%(95% CI 18.3-36.8%),3个月时GI或GU平均生活质量无统计学显著损害。

要点

  • 急性≥2级GI副作用15.5%,低于预设35%阈值,单侧95%置信上限22.8%。
  • 急性≥2级GU副作用26.8%(95% CI 18.3-36.8%)。
  • 3个月时患者报告的GI或GU平均生活质量无统计学显著损害。

核心结论

  • 前列腺及盆腔ENI中度大分割放疗联合大体病灶推量,急性副作用低于预期,3个月时患者报告的GI或GU平均生活质量无统计学显著损害。

研究设计与样本

  • 前瞻性2期单臂研究,纳入100例高危或淋巴结阳性前列腺癌患者,97例完成治疗。
  • 放疗方案:前列腺60 Gy/20次,盆腔ENI 48 Gy,联合ADT;允许同步整合推量至前列腺内大体病灶68 Gy和影像学受累淋巴结55 Gy。
  • 主要终点为放疗后3个月急性GI副作用(CTCAE v5.0),预设急性≥2级GI副作用不超过35%。

主要发现

  • 急性≥2级GI副作用发生率为15.5%(单侧95%置信上限22.8%)。
  • 急性≥2级GU副作用发生率为26.8%(95% CI 18.3-36.8%)。
  • 单变量分析中,较高的直肠和肠道D1cc及前列腺内推量与急性GI副作用增加显著相关。
  • 3个月时GI或GU平均生活质量无统计学显著损害。

关键数值与推荐

  • 主要终点预设假设:急性≥2级GI副作用不超过35%。
  • 实际急性≥2级GI副作用15.5%,单侧95%置信上限22.8%。
  • 急性≥2级GU副作用26.8%(95% CI 18.3-36.8%)。

临床怎么用

  • 对于高危或淋巴结阳性前列腺癌,可考虑前列腺及盆腔ENI中度大分割放疗联合ADT,并对大体病灶行同步整合推量。
  • 治疗计划中应关注直肠和肠道D1cc及前列腺内推量对急性GI副作用的影响。

局限性

  • 单臂2期研究,无对照组。
  • 样本量100例,随访仅报告3个月急性期结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the safety of moderately hypofractionated radiotherapy to the prostate and pelvic elective nodal irradiation (ENI) with intraprostatic and nodal boost in patients with high-risk prostate cancer. METHODS: In this prospective phase 2 single-arm study, patients with high-risk or node-positive prostate cancer received external beam radiotherapy to the prostate and ENI with moderate hypofractionation (60 Gy in 20 fractions to the prostate; 48 Gy ENI) with ADT. Simultaneous integrated boosts were allowed to 68 Gy to intraprostatic gross disease (MRI-defined) and 55 Gy to radiographically-involved nodes. The primary endpoint was acute gastrointestinal (GI) side effects (CTCAE v5.0) at 3 months following radiotherapy, with an a priori hypothesis that acute grade ≥ 2 GI side effects would not exceed 35%. Secondary endpoints included acute genitourinary (GU) side effects and quality of life (QoL) (EPIC-26 and IPSS). RESULTS: 100 patients were enrolled; 97 completed treatment. Median age was 73, 49% had grade group 4-5 disease, median PSA was 22.2 ng/mL, 21% were cN1. 23 (24%) and 18 (19%) of patients received intraprostatic and nodal boosts, respectively. The rate of acute grade ≥ 2 GI side effects was 15.5% (one-sided 95% upper confidence bound22.8%). On univariable analysis, higher rectal and bowel D1cc and intraprostatic boost were significantly associated with increased acute GI side effects. The rate of grade ≥ 2 acute GU side effects was 26.8% (95% CI 18.3-36.8%). There was no statistically significant detriment to mean GI or GU QoL at 3 months post-treatment. CONCLUSIONS: Moderately hypofractionated radiotherapy to the prostate and ENI with boosts to gross disease was associated with lower-than-expected side effects and no statistically significant detriment to patient-reported mean GI or GU QoL at 3 months post-treatment.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Mathew JM, Bacon H, Winter J, et al. Moderate hypofractionated boost to the prostate with pelvic radiotherapy in high-risk prostate cancer (MOB-RT) - a phase 2 study: acute safety and quality of life outcomes. Radiother Oncol. 2026. PMID: 42177994. doi:10.1016/j.radonc.2026.111614

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。